Filing Details

Accession Number:
0001628280-22-023325
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-19 13:07:10
Reporting Period:
2022-08-17
Accepted Time:
2022-08-19 13:07:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1501697 X4 Pharmaceuticals Inc XFOR Biological Products, (No Disgnostic Substances) (2836) 273181608
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1880179 Mary Dibiase C/O X4 Pharmaceuticals Inc.
61 North Beacon Street 4Th Floor
Boston MA 02134
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-08-17 1,713 $0.00 177,896 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.150 to $1.215, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. Of the shares of common stock reported, 164,504 shares represent unvested restricted stock units.